メンバー

スタッフ

English Information

はぎわら やすひろ

萩原 康博助教    

HAGIWARA Yasuhiro

健康科学・看護学専攻 生物統計学分野

hagiwara [at] epistat.m.u-tokyo.ac.jp

研究

生物統計学の研究と実践をしています。
生物統計学の研究としては、(1)臨床研究や疫学研究における因果推論手法と(2)HEOR (Health Economics and Outcomes Research) での統計手法について研究しています。いま取り組んでいる具体的な研究テーマは以下の通りです。

- 臨床研究や疫学研究における因果推論手法
・生存時間アウトカムに対する時間依存性治療の効果推定
(Hagiwara et al. Biometrics 2019+. Hagiwara et al. Biometrics 2020+.)
・二値アウトカムの恒等・対数リンク関数を用いた統計解析
(Hagiwara et al. Am J Epidemiol 2018.)

- HEORでの統計手法
・医療経済評価における非選好型尺度からQOL値へのマッピング手法
(Hagiwara et al. Value Health 2020. Hagiwara et al. submitted.)
・価値にもとづく医薬品・医療機器の価格設定(value-based pricing)における統計的推測
・医療経済評価における生存の外挿手法

生物統計学の実践としては、がん領域を中心に様々な臨床研究に生物統計家として参加しています。その中でも健康関連QOL研究には、特に力を入れて取り組んでいます(Hagiwara et al. ESMO Open 2017. Hagiwara et al. Eur J Cancer 2018. Hagiwara et al. Pharmacoeconomics 2018. など)。

経歴

2010.4 東京大学文科三類 入学
2014.3 東京大学医学部健康総合科学科 卒業 学士(保健学)
2016.3 東京大学大学院医学系研究科公共健康医学専攻専門職学位課程 修了 公衆衛生学修士(専門職)
2019.3 東京大学大学院医学系研究科健康科学・看護学専攻博士後期課程 修了 博士(保健学)
2019.4 東京大学大学院医学系研究科健康科学・看護学専攻生物統計学分野 助教

活動

所属学会:
-日本計量生物学会(正会員)
-International Biometric Society(会員)
-International Society of Pharmacoeconomics and Outcome Reserrch(会員)

受賞歴:
-東京大学 大学院医学系研究科 公共健康医学専攻 平成27年度課題研究発表 優秀賞
-ISPOR (International Society for Pharmacoeconomics and Outcome Research) Asia Pacific 2018 Best Student Poster Research Presentation

競争的研究資金:
-日本学術振興会 科学研究費助成事業 研究活動スタート支援 2019年8月~2021年3月
(医療経済評価における非選好型尺度からQOL値へのマッピング手法に関する基礎的研究、19K24193、研究代表者)

学外活動:
-公益財団法人パブリックヘルスリサーチセンター ヘルスアウトカムリサーチ支援事業 運営委員(2017年10月~)

  1. Hagiwara Y, Kawahara T, Shiroiwa T. What is a valid mapping algorithm in cost-utility analyses? A response from a missing data perspective. Value Health. https://doi.org/10.1016/j.jval.2020.03.020
  2. Hagiwara Y, Shinozaki T, Mukai H, Matsuyama Y. Sensitivity analysis for subsequent treatments in confirmatory oncology clinical trials: a two-stage stochastic dynamic treatment regime approach. Biometrics. 2020. doi: 10.1111/biom.13296. Online ahead of print.
  3. Hagiwara Y, Shinozaki T, Matsuyama Y. G‐estimation of structural nested restricted mean time lost models to estimate effects of time‐varying treatments on a failure time outcome. Biometrics. https://doi.org/10.1111/biom.13200
  4. Yoshida T, Uchino S, Sasabuchi Y, Hagiwara Y, the AFTER-ICU study group. Prognostic impact of sustained new-onset atrial fibrillation in critically ill patients. Intensive Care Med. 2019. https://doi.org/10.1007/s00134-019-05822-8
  5. Shitara K, Yamanaka T, Denda T, Tsuji Y, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Yoshino T. REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients. Ann Oncol. 2019;30:259-265.
  6. Ishimaru M, Matsui H, Ono S, Hagiwara Y, Morita K, Yasunaga H. Preoperative oral care and effect on postoperative complications after major cancer surgery. Br J Surg. 2018;105:1688-1696.
  7. Hagiwara Y, Fukuda M, Matsuyama Y. The number of events per confounder for valid estimation of risk difference using modified least-squares regression. Am J Epidemiol. 2018;187:2481-2490.
  8. Hagiwara Y, Ohashi Y, Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T. Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: results from a randomized phase III trial (JASPAC 01). Eur J Cancer. 2018;93:79-88.
  9. Takayasu K, Arii S, Sakamoto M, Matsuyama Y, Kudo M, Kaneko S, Nakashima O, Kadoya M, Izumi N, Takayama T, Ku Y, Kumada T, Kubo S, Kokudo T, Hagiwara Y, Kokudo N, Liver Cancer Study Group of Japan. Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analyzed with propensity score weighting. Liver Int. 2018;38:484-493.
  10. Kawahara T, Shimozuma K, Shiroiwa T, Hagiwara Y, Uemura Y, Watanabe T, Taira N, Fukuda T, Ohashi Y, Mukai H. Patient-reported outcome results from the open-label randomized phase III SELECT BC trial evaluating first-line S-1 therapy for metastatic breast cancer. Oncology. 2018;94:107-115
  11. Shiroiwa T, Fukuda T, Shimozuma K, Mouri M, Hagiwara Y, Kawahara T, Ohsumi S, Hozumi Y, Sagara Y, Ohashi Y, Mukai H. Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial. BMC Cancer. 2017;17:773.
  12. Hagiwara Y, Shiroiwa T, Shimozuma K, Kawahara T, Uemura Y, Watanabe T, Taira N, Fukuda T, Ohashi Y, Mukai H. Impact of adverse events on health utility and health-related quality of life in patients receiving first-line chemotherapy for metastatic breast cancer: results from the SELECT BC study. Pharmacoeconomics. 2018;36:215-223.
  13. Mukai H, Hagiwara Y, Imi K, Isaka H, Watanabe K, Matsuyama Y for the SELECT BC Study Group. The impact of treatment preferences in second-line chemotherapy on the prognosis of HER2-negative metastatic breast cancer. Oncology. 2017;93:315-322.
  14. Shinozaki T, Hagiwara Y, Matsuyama Y. Re. Biases in randomized trials: a conversation between trialists and epidemiologists (Letter). Epidemiology. 2017; 28(4): e40-e41.
  15. Hagiwara Y, Ohashi Y, Okusaka T, Ueno H, Ioka T, Boku N, Egawa S, Hatori T, Furuse J, Mizumoto K, Ohkawa S, Yamaguchi T, Yamao K, Funakoshi A, Cheng AL, Kihara K, Sato A, Tanaka M. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study. ESMO Open. 2017;2:e000151.
  16. Yamaue H, Shimizu A, Hagiwara Y, Sho M, Yanagimoto H, Nakamori S, Ueno H, Ishii H, Kitano M, Sugimori K, Maguchi H, Ohkawa S, Imaoka H, Hashimoto D, Ueda K, Nebiki H, Nagakawa T, Isayama H, Yokota I, Ohashi Y, Shirasaka T. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer. Cancer Chemother Pharmacol. 2017;79:813-823.
  17. Shiroiwa T, Fukuda T, Shimozuma K, Mouri M, Hagiwara Y, Doihara H, Akabane H, Kashiwaba M, Watanabe T, Ohashi Y, Mukai H. Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial. Qual Life Res. 2017;26:445-453.

  1. Hagiwara Y, Kawahara T, Shiroiwa T. What is a valid mapping algorithm in cost-utility analyses? An answer from a missing data perspective. International Society for Pharmacoeconomics and Outcome Research Europe 2019. Copenhergen, Denmark. November 2019. PNS323.
  2. Takeuchi Y, Ogawa M, Hagiwara Y, Matsuyama Y. Multiple imputation for survival analysis with missing covariates using non-parametric estimation. 12th Asian Conference on Pharmacoepidemiology and 25th Japanese Conference on Pharmacoepidemiology joint meeting. Kyoto. Oct 2019.
  3. Kobayashi K, Taira N, Sawaki M, Sagawa N, Baba S, Saito T, Kawahara T, Hagiwara Y, Uemura Y, Shimozuma K, Ohashi Y, Mukai H. Patient-reported outcomes with trastuzumab monotherapy versus trastuzumab plus standard chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients (RESPECT): A randomized, open-label, phase 3 clinical trial. San Antonio Breast Cancer Symposium 2018. San Antonio, the United States, December 2018.
  4. Takahashi M, Sawaki M, Hagiwara Y, Uemura Y, Kawahara T, Shimozuma K, Ohashi Y, Saito T, Baba S, Kobayashi K, Mukai H, Taira N. Analysis of cognitive function in elderly HER2-positive breast cancer patients receiving either trastuzumab monotherapy or trastuzumab plus chemotherapy as a postoperative adjuvant treatment: A cognitive function sub-study of a randomized, open-label, phase 3 clinical trial (RESPECT trial). San Antonio Breast Cancer Symposium 2018. San Antonio, the United States, December 2018.
  5. Hagiwara Y, Taira N, Saito T, Baba S, Kobayashi K, Kawahara T, Shiroiwa T, Fukuda T, Shimozuma K, Uemura Y, Mukai H, Ohashi Y, Sawaki M. The EQ-5D index of elderly patients with HER-2 positive breast cancer: results from the randomized N-SAS BC 07 trial for adjuvant trastuzumab with and without chemotherapy. International Society for Pharmacoeconomics and Outcome Research Asia Pacific 2018 Conference. Tokyo, Japan. September 2018. PCN65.
  6. Hagiwara Y, Shinozaki T, Matsuyama Y. G-estimation of structural nested restricted mean time lost models to estimate effect of time-varying treatment on survival outcome. 29th International Biometric Conference. Barcelona, Spain. July 2018. CS41.1.
  7. Yoshino T, Yamanaka T, Denda T,Tsuji Y, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Shitara K. REVERCE: randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: quality of life analysis. European Society for Medical Oncology World Congress on Gastrointestinal Cancer 2018. Barcelona, Spain. June 2018.
  8. Tsuji Y, Shitara K, Yamanaka T, Denda T, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Yoshino T. REVERCE: randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated With fluoropyrimidine, oxaliplatin, and irinotecan— biomarker analysis. American Society of Clinical Oncology Annual Meeting 2018, Chicago, US, June 3, 2018. Abstract 3510.
  9. Shiroiwa T, Fukuda T, Shimozuma K, Mouri M, Hagiwara Y, Kawahara T, Ohsumi S, Hozumi Y, Sagara Y, Ohashi Y, Mukai H. Cost-effectiveness of first-line S-1 therapy for metastatic breast cancer patients compared with taxanes: an analysis based on the randomized phase III SELECT BC trial. International Society for Pharmacoeconomics and Outcome Research 19th Annual European Congress, Vienna, Austria, November 2. Abstract PCN161.
  10. Hagiwara Y, Shimozuma K, Shiroiwa T, Kawahara T, Uemura Y, Watanabe T, Taira N, Fukuda T, Ohashi Y, Mukai H. Impacts of adverse events on health-related quality of life in patients receiving first-line chemotherapy for metastatic breast cancer : results from randomized phase III SELECT BC study. International Society for Pharmacoeconomics and Outcome Research 19th Annual European Congress, Vienna, Austria, November 2. Abstract PCN204.
  11. Kawahara T, Shimozuma K, Shiroiwa T, Hagiwara Y, Uemura Y, Watanabe T, Fukuda T, Ohashi Y, Mukai H. Responder analyses of patient-reported outcomes for evaluating the clinical significance of first-line S-1 over taxane therapy among patients with metastatic breast cancer: the open-label randomized phase III SELECT BC trial. International Society for Quality of Life Research 23rd Annual Conference, Copenhagen, Denmark, October 21. Abstract 2029.
  12. Sho M, Shimizu A, Yanagimoto H, Nakamori S, Okusaka T, Ishii H, Kitano M, Sugimori K, Maguchi H, Ohkawa S, Imaoka H, Hashimoto D, Ueda K, Nebiki H, Nagakawa T, Isayama H, Hagiwara Y, Ohashi Y, Shirasaka T, Yamaue H. Multicenter randomized phase II study comparing alternate-day oral therapy using S-1 with the standard regimen as a first-line treatment for patients with locally advanced and metastatic pancreatic cancer: PAN-01 study. American Society for Clinical Oncology annual meeting 2016, Chicago, US, June, 2016. J Clin Oncol. 2016; 34(suppl; abstr 4107).
  13. Hagiwara Y, Shinozaki T, Matsuyama Y. Estimation of modified effectiveness in randomized trials with subsequent treatments using dynamic marginal structural models. UK Causal Inference Meeting 4th annual meeting, London, England, April 13, 2016. P18.
  14. Fukuda T, Shiroiwa T, Simozuma K, Mori M, Doihara H, Akabane H, Kashiwaba M, Watanabe T, Hagiwara Y, Ohashi Y, Mukai H. Long-term EQ-5D score for patients with metastatic breast cancer; comparison of first-line oral S-1 and Taxane therapies in the randomized SLECT trial. International Society for Pharmacoeconomics and Outcome Research 18th Annual European Congress, Milan, Italy, November 9, 2015. Abstract PCN210.

学会発表(国内)

  1. 山内理海,設楽紘平,山中竹春,傳田忠道,辻靖,小松嘉人,小林良充,古瀬 純司,加藤健志,沖英次,安藤高志,萩原康博,大橋靖雄,吉野孝之.REVERCE: randomized phase II study of regorafenib followed by cetuximab vs. reverse sequence for colorectal cancer.第16回日本臨床腫瘍学会学術集会.神戸.2018年7月.
  2. 萩原康博,福田武蔵,松山裕.Modified Least-Squares回帰による妥当なリスク差推定に必要な1交絡変数当たりのイベント数.2018年度日本計量生物学会年会,東京,2018/3/30.
  3. 遠山竜也,渡辺隆紀,下妻晃二郎,白岩健,福田敬,毛利光子,上村夕香理,川原拓也,萩原康博,大橋靖雄,向井博文.SELECT BC試験におけるHRQOLと医療経済評価.第23回日本乳癌学会学術総会,東京,2015/7/2.
  4. 萩原康博,木原清敬,松山裕,大橋靖雄.質調整生存時間の効用値欠測と生存時間打ち切りに対する感度解析:進行膵癌臨床試験データへの適用.2014年度日本計量生物学会年会,東京,2014/5/24.

  1. Hagiwara Y. Estimation of modified effectiveness in confirmatory cancer clinical trials using dynamic marginal structural models. PeSeTo International Symposium on Public Health 2016, Tokyo, Japan, March 15, 2016.

シンポジウム(国内)

  1. 萩原康博.G-estimation:治療の影響を受ける交絡変数の調整.NDB・DPCデータベース研究人材育成<短期集中セミナー>,東京,2019/8/6.
  2. 萩原康博,大橋靖雄.QOLの統計的評価:最近の成果から.第89回QOL研究会,東京,2017/9/17.
  3. 萩原康博.SELECT BC のQOL、医療経済評価およびEQ-5Dについて: EQ-5Dへの有害事象の影響.第11回CSP-HOR年会,東京,2017/7/1.
  4. 萩原康博.QALYの解析に関わる統計的な問題.第10回CSP-HOR年会,東京,2016/8/20.
  5. 萩原康博.臨床試験においてMIDをendpointにおいた場合の課題:Time to Deterioration解析を中心に.QOL/PRO研究会 第5回研究セミナー,草津,2015/7/11.

TOP